Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects

Journal of Lipid Research

Volumn 51, Issue 8, 2010, Pages 2413-2421

  Ooi, Esther M M ^a   Janus, Edward D ^b   Grant, Susan J ^c   Sinclair, Lucia M T ^c   Barrett, P Hugh R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PRINCESS MARGARET HOSPITAL   (New Zealand)

Author keywords

apoE2 E2 genotype; Kinetics; Type III hyperlipidemia

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; INTERMEDIATE DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN E;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PATHOGENESIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ALLELE; CLINICAL TRIAL; GENETICS; HETEROZYGOTE; KINETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ALLELES; APOLIPOPROTEIN B-100; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERLIPIDEMIAS; KINETICS; MALE; MIDDLE AGED;

EID: 77956859513     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M004705     Document Type: Article

References (48)

1. Weisgraber, K. H. 1994. Apolipoprotein E: structure-function relationships. Adv. Protein Chem. 45: 249-302.
2. Gibson, J. C., and W. V. Brown. 1988. Effect of lipoprotein lipase and hepatic triglyceride lipase activity on the distribution of apolipoprotein E among the plasma lipoproteins. Atherosclerosis. 73: 45-55.
3. Mahley, R. W., and Y. Huang. 1999. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr. Opin. Lipidol. 10: 207-217.
4. Greenow, K., N. J. Pearce, and D. P. Ramji. 2005. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 83: 329-342.
5. Davignon, J., R. E. Gregg, and C. F. Sing. 1988. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 8: 1-21.
6. Mahley, R. W., Y. Huang, and S. C. Rall, Jr. 1999. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid Res. 40: 1933-1949.
7. Stalenhoef, A. F., M. J. Malloy, J. P. Kane, and R. J. Havel. 1986. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J. Clin. Invest. 78: 722-728.
8. Hopkins, P. N., L. L. Wu, S. C. Hunt, and E. A. Brinton. 2005. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J. Am. Coll. Cardiol. 45: 1003-1012.
9. Janus, E. D., S. Grant, C. J. Lintott, and M. R. Wardell. 1985. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis. 57: 249-266.
10. Wardell, M. R., S. O. Brennan, E. D. Janus, R. Fraser, and R. W. Carrell. 1987. Apolipoprotein E2-Christchurch (136 Arg - Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J. Clin. Invest. 80: 483-490.
11. Wardell, M. R., S. C. Rall, Jr., S. O. Brennan, E. R. Nye, P. M. George, E. D. Janus, and K. H. Weisgraber. 1990. Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity. J. Lipid Res. 31: 535-543.
12. McFarlane, A. S. 1958. Efficient trace-labelling of proteins with iodine. Nature. 182: 53.
13. Janus, E. D., A. M. Nicoll, P. R. Turner, P. Magill, and B. Lewis. 1980. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur. J. Clin. Invest. 10: 161-172.
14. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
15. Kane, J. P. 1973. A rapid electrophoretic technique for identification of subunit species of apoproteins in serum lipoproteins. Anal. Biochem. 53: 350-364.
16. Margolis, S., and R. G. Langdon. 1966. Studies on human serum beta-1-lipoprotein. I. Amino acid composition. J. Biol. Chem. 241: 469-476.
17. Wardell, M. R., P. A. Suckling, and E. D. Janus. 1982. Genetic variation in human apolipoprotein E. J. Lipid Res. 23: 1174-1182.
18. Reardon, M. F., M. E. Poapst, and G. Steiner. 1982. The independent synthesis of intermediate density lipoproteins in type III hyperlipoproteinemia. Metabolism. 31: 421-427. (Pubitemid 12155446)
19. Packard, C. J., R. J. Clegg, M. H. Dominiczak, A. R. Lorimer, and J. Shepherd. 1986. Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J. Lipid Res. 27: 930-938.
20. Beltz, W. F., Y. A. Kesaniemi, B. V. Howard, and S. M. Grundy. 1985. Development of an integrated model for analysis of the kinetics of apolipoprotein B in plasma very low density lipoproteins, intermediate density lipoproteins, and low density lipoproteins. J. Clin. Invest. 76: 575-585.
21. Berman, M. 1979. Kinetic analysis of turnover data. Prog. Biochem. Pharmacol. 15: 67-108.
22. Turner, P. R., C. Cortese, R. Wootton, C. Marenah, N. E. Miller, and B. Lewis. 1985. Plasma apolipoprotein B metabolism in familial type III dysbetalipoproteinaemia. Eur. J. Clin. Invest. 15: 100-112.
23. Haffner, S. M., R. S. Kushwaha, and W. R. Hazzard. 1989. Metabolism of chylomicrons in subjects with dysbetalipoproteinaemia (type III hyperlipoproteinaemia). Eur. J. Clin. Invest. 19: 486-490.
24. Redgrave, T. G., G. F. Watts, I. J. Martins, P. H. Barrett, J. C. Mamo, S. B. Dimmitt, and A. D. Marais. 2001. Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. J. Lipid Res. 42: 710-715.
25. Tremblay, A. J., B. Lamarche, I. L. Ruel, J. C. Hogue, Y. Deshaies, C. Gagne, and P. Couture. 2006. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia. Atherosclerosis. 188: 203-212.
26. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes. 1997. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem. J. 328: 745-750.
27. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
28. Kushwaha, R. S., S. M. Haffner, D. M. Foster, and W. R. Hazzard. 1985. Compositional and metabolic heterogeneity of alpha 2-and beta-very-low-density lipoproteins in subjects with broad beta disease and endogenous hypertriglyceridemia. Metabolism. 34: 1029-1038.
29. Berman, M., M. Hall III, R. I. Levy, S. Eisenberg, D. W. Bilheimer, R. D. Phair, and R. H. Goebel. 1978. Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J. Lipid Res. 19: 38-56.
30. Vega, G. L., C. East, and S. M. Grundy. 1988. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis. 70: 131-143.
31. Crawford, D. C., A. S. Nord, M. D. Badzioch, J. Ranchalis, L. A. McKinstry, M. Ahearn, C. Bertucci, C. Shephard, M. Wong, M. J. Rieder, et al. 2008. A common VLDLR polymorphism interacts with APOE genotype in the prediction of carotid artery disease risk. J. Lipid Res. 49: 588-596.
32. Rall, S. C., Jr., K. H. Weisgraber, T. L. Innerarity, and R. W. Mahley. 1983. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J. Clin. Invest. 71: 1023-1031.
33. Ooi, E. M., P. H. Barrett, D. C. Chan, and G. F. Watts. 2008. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin. Sci. (Lond.). 114: 611-624.
34. Henneman, P., F. van der Sman-de Beer, P. H. Moghaddam, P. Huijts, A. F. Stalenhoef, J. J. Kastelein, C. M. van Duijn, L. M. Havekes, R. R. Frants, K. W. van Dijk, et al. 2009. The expression of type III hyperlipoproteinemia: involvement of lipolysis genes. Eur. J. Hum. Genet. 17: 620-628.
35. Demant, T., J. Shepherd, and C. J. Packard. 1988. Very low density lipoprotein apolipoprotein B metabolism in humans. Klin. Wochenschr. 66: 703-712.
36. Kesaniemi, Y.A., Vega, G.L., and Grundy, S.M. 1985. ApoB kinetics in normal vs. hyperlipidemic man: review of current data. J. Clin. Invest. 76: 586-595.
37. Egusa, G., W. F. Beltz, S. M. Grundy, and B. V. Howard. 1985. Influence of obesity on the metabolism of apolipoprotein B in humans. J. Clin. Invest. 76: 596-603.
38. Kesaniemi, Y. A., W. F. Beltz, and S. M. Grundy. 1985. Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease. J. Clin. Invest. 76: 586-595.
39. Evans, D., U. Seedorf, and F. U. Beil. 2005. Polymorphisms in the apolipoprotein A5 (APOA5) gene and type III hyperlipidemia. Clin. Genet. 68: 369-372.
40. Geisel, J., T. Bunte, M. Bodis, K. Oette, and W. Herrmann. 2002. Apolipoprotein E2/E2 genotype in combination with mutations in the LDL receptor gene causes type III hyperlipoproteinemia. Clin. Chem. Lab. Med. 40: 475-479.
41. de Beer, F., A. F. Stalenhoef, N. Hoogerbrugge, J. J. Kastelein, J. A. Gevers Leuven, C. M. van Duijn, L. M. Havekes, and A. H. Smelt. 2002. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 ? Cys) homozygotes is associated with hyperinsulinemia. Arterioscler. Thromb. Vasc. Biol. 22: 294-299.
42. van Dijk, K. W., M. H. Hofker, and L. M. Havekes. 1999. Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models. Curr. Atheroscler. Rep. 1: 101-107.
43. Chung, B. H., and J. P. Segrest. 1983. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein density fraction. J. Lipid Res. 24: 1148-1159.
44. Mann, W. A., R. E. Gregg, D. L. Sprecher, and H. B. Brewer, Jr. 1989. Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia. Biochim. Biophys. Acta. 1005: 239-244.
45. Havekes, L., E. de Wit, J. G. Leuven, E. Klasen, G. Utermann, W. Weber, and U. Beisiegel. 1986. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum. Genet. 73: 157-163.
46. Cohn, J. S., R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon. 2003. Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism. J. Lipid Res. 44: 1976-1983.
47. Murdoch, S. J., A. P. Boright, A. D. Paterson, B. Zinman, M. Steffes, P. Cleary, K. Edwards, S. S. Marcovina, J. Q. Purnell, and J. D. Brunzell. 2007. LDL composition in E2/2 subjects and LDL distribution by Apo E genotype in type 1 diabetes. Atherosclerosis. 192: 138-147.
48. Jiang, X. C., and H. W. Zhou. 2006. Plasma lipid transfer proteins. Curr. Opin. Lipidol. 17: 302-308.